Disease · MONDO_0004872

hemorrhoid

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hemorrhoid. Diseases, record MONDO_0004872. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004872

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hemorrhoid; Open Targets
Open Targets ID: MONDO_0004872; Open Targets
Other names: Haemorrhoids, Hemorrhoids, hemorrhoidal disease; Open Targets
Disease Ontology: DOID:9746; Disease Ontology
MeSH: D006484; MeSH
NCI Thesaurus: C26792; NCI Thesaurus
Highest stage of its drugs: Approval, for 30 of its 41 drugs, from ATC, DailyMed, PMDA and TTD; Open Targets

Drugs41

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LIDOCAINE	CHEMBL79	Small molecule	Approval	ATC and DailyMed	13	3	3	Drugs and targets
DIOSMIN	CHEMBL231884	Small molecule	Approval	TTD	3	2	0	Drugs and targets
WITCH HAZEL	CHEMBL2108698		Approval	DailyMed	15	1	1	Drugs and targets
PRAMOXINE HYDROCHLORIDE	CHEMBL1201171	Small molecule	Approval	DailyMed	10	1	1	Drugs and targets
BENZOCAINE	CHEMBL278172	Small molecule	Approval	ATC and DailyMed	3	1	1	Drugs and targets
FLUOCORTOLONE	CHEMBL251634	Small molecule	Approval	ATC	2	1	1	Drugs and targets
HYDROCORTISONE	CHEMBL389621	Small molecule	Approval	ATC	2	1	1	Drugs and targets
PHENYLEPHRINE HYDROCHLORIDE	CHEMBL1200339	Small molecule	Approval	DailyMed	20	0	0	Drugs and targets
GLYCERIN	CHEMBL692	Small molecule	Approval	DailyMed	9	0	0	Drugs and targets
ZINC OXIDE	CHEMBL3988900	Small molecule	Approval	DailyMed	7	0	0	Drugs and targets

1 to 10 of 41

See all 41 drugs

Targets37

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	9	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
SCN10A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker; Sodium channel protein type X alpha subunit blocker	Approval	https://conductscience.org/library/genes/6336	Drugs and targets
SCN4A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Approval	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker; Sodium channel protein type V alpha subunit blocker	Approval	https://conductscience.org/library/genes/6331	Drugs and targets
SCN11A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6328	Drugs and targets
SCN7A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6332	Drugs and targets
SCN8A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6334	Drugs and targets

1 to 10 of 37

See all 37 targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00405288	The Safety of Proctofoam-HC in the Third Trimester of Pregnancy		408	2014-02-05	Hemorrhoids, Pregnancy	HYDROCORTISONE, PRAMOXINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT03335774	Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids	Phase 2	103	2022-09-13	Internal Hemorrhoids	HYDROCORTISONE ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03757078	Study to Find Out How Symptoms Severity Changes During the Standard Course of Treatment With the Cream Relief Pro and Suppositories Relief Pro (Active Ingredients Are Fluocortolone + Lidocaine) in Patients Suffering From Twisted and Bulging Veins in the Rectal Area (Acute Hemorrhoids)		1,000		Acute Hemorrhoids	FLUOCORTOLONE, LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT01355874	Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids	Phase 3	403		Internal Hemorrhoids	IFERANSERIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02689856	Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids	Phase 2	211		Hemorrhoids	HYDROCORTISONE ACETATE, LIDOCAINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT03791775	Efficacy and Safety of Polidocanol Foam 3% in the Treatment of II Degree Hemorrhoidal Disease	Phase 2	183		Second-degree Hemorrhoids	POLIDOCANOL	Its record names the disease	ClinicalTrials.gov
NCT07442539	The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Hemorrhoid Surgery	Not applicable	156		Hemorrhoid Surgery, Liposome Bupivacaine, Pain Management, Local Infiltration	BUPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT01913158	Safety and Efficacy Study of Anucort HC TM 25mg Rectal Suppositories to Treat Symptomatic Internal Hemorrhoids	Phase 2	150		Internal Hemorrhoids	HYDROCORTISONE ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01961739	Topical 2% Lidocaine for the Treatment of Symptomatic Hemorrhoids	Phase 2/3	138		Hemorrhoids	LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT01483833	Efficacy Study of Iferanserin to Treat Hemorrhoids	Phase 2	121		Hemorrhoids	IFERANSERIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Proctofoam-HC® vs Control: serious adverse events	0 of 204	0 of 204	408	NCT00405288	Trial comparisons
Hydrocortisone Acetate Suppository, 25 mg vs Placebo (Vehicle) Suppository: deaths from any cause	0 of 50	0 of 51	101	NCT03335774	Trial comparisons
Hydrocortisone Acetate Suppository, 25 mg vs Placebo (Vehicle) Suppository: serious adverse events	0 of 50	0 of 51	101	NCT03335774	Trial comparisons

Papers from its trials53

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39228195	RESULT	1	PubMed
34530908	RESULT	1	PubMed
30485654	RESULT	1	PubMed
30451751	RESULT	2	PubMed
30159627	RESULT	1	PubMed
26728606	RESULT	1	PubMed
23971772	RESULT	1	PubMed
23775099	RESULT	1	PubMed
23543083	RESULT	1	PubMed
23294756	RESULT	1	PubMed

1 to 10 of 53

See all 53 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004872

GET https://conductscience.org/api/diseases/v1/MONDO_0004872/drugs?page=2

API reference For AI assistants